The global biopharmaceutical sector generated $16 billion in the third quarter of the year, adding to the almost $38 billion it raised in the first half of the year. According to BioWorld data, the collective $54 billion the sector has brought in at the three quarter post is 4 percent more than the total it raised at this point last year. The sector is poised to post a record year for the amount of cash it hauled in and to top the $69 billion raised in 2015. Read More
In the third quarter, biotech investors dramatically dialed down their risk tolerance. As a result, share values of small and midsized drug developers dipped almost 6 percent in September and, as a result, the BioWorld Drug Developers index returned a flat third quarter. In contrast, blue chip biopharmas enjoyed an excellent quarter, with the BioWorld Biopharmaceutical index outperforming the general markets. Read More
